Who Owns Teva Pharmaceuticals?
Teva Pharmaceutical Industries Limited is an independent, publicly traded Israeli multinational pharmaceutical company. The company trades on the New York Stock Exchange under ticker TEVA and on the Tel Aviv Stock Exchange. Teva is the world's largest manufacturer of generic medications, producing over 3,500 generic drug products globally. The company also markets branded specialty medications and reported approximately 16.5 billion US dollars in revenue for FY2024.
Parent Company
Teva Pharmaceutical Industries
Founded
1901
Status
Publicly Traded
Headquarters
Tel Aviv, Israel
Who Owns Teva Pharmaceuticals?
- Parent Company: Teva Pharmaceutical Industries
- Ownership Type: Public
- Company Type: Publicly Traded
- Stock Ticker: NYSE: TEVA
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Teva Pharmaceuticals | Teva Pharmaceutical Industries | Public |
History of Teva Pharmaceuticals
- Founded: 1901
- Founders: Moshe Levontin, Yitzhak Elstein, Chaim Salomon
Teva traces its origins to 1901, when a small drug distribution business was established in Jerusalem. The company incorporated formally in 1944 and began manufacturing pharmaceutical products in Israel. By the 1950s and 1960s, Teva had established itself as Israel's primary domestic pharmaceutical manufacturer.
International expansion began in the 1980s. Teva entered the United States market through a series of acquisitions, recognizing that the 1984 Hatch-Waxman Act, which created the modern US generic drug approval system, offered significant commercial opportunity for a company with expertise in generic manufacturing.
The 1985 acquisition of Lemmon Company gave Teva a direct US manufacturing and distribution presence. Further US acquisitions followed over the following two decades. By the early 2000s, Teva was among the largest players in the US generic drug market.
The launch of generic copaxone, Teva's branded multiple sclerosis treatment, in biosimilar competition in the late 2010s was a turning point. Copaxone had been Teva's highest-margin product. Its revenue declined sharply as generic competition entered. This revenue loss coincided with rising debt from the 2016 Allergan Generics acquisition.
In 2016, Teva acquired Allergan plc's generic drug business (the former Actavis Generics) for approximately 40.5 billion US dollars, the largest acquisition in Teva's history and one of the largest pharmaceutical acquisitions globally. The deal made Teva the undisputed world leader in generic drugs by market share but also loaded the company with approximately 35 billion US dollars in debt.
From 2017 onward, Teva undertook a major restructuring program. The company sold non-core assets, closed manufacturing facilities, reduced its workforce by approximately 30%, and renegotiated debt. CEO Kare Schultz led the restructuring from 2017 to 2022. Richard Francis succeeded him in 2023.
As of 2024, Teva's restructuring is broadly complete. The company reported approximately 16.5 billion US dollars in revenue for FY2024 and has significantly reduced its debt burden. The company's pipeline includes specialty medications and biosimilars, and Teva has invested in building a portfolio of innovative products alongside its generic core.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries operates as one of the world's largest generic pharmaceutical companies with operations in more than 60 countries. The company develops, manufactures, and markets generic medicines, specialty medicines, and active pharmaceutical ingredients.
The company's business model combines high-volume generic drug production with specialty pharmaceutical development. Teva generates revenue through generic drug sales, specialty medicines, and API sales to other pharmaceutical companies. The company is known for its expertise in developing complex generic formulations and biosimilar products.
Teva Pharmaceutical Industries employs approximately 37,000 people worldwide, with its headquarters in Tel Aviv, Israel, and major manufacturing and research facilities across North America, Europe, and Asia. The company continues to invest in research and development, complex generics, and specialty medicines.
- Founded: 1901
- Headquarters: Tel Aviv, Israel
- Company Type: Publicly Traded
- Stock: NYSE: TEVA
- Revenue: approximately $15.9 billion (FY2024)
- Employees: Approximately 37,000
Where Is Teva Pharmaceuticals Made / Based?
- Headquarters: Tel Aviv, Israel
- Manufacturing / Operations: Israel, United States, Hungary, India, Poland, Czech Republic, Germany, United Kingdom
Teva Pharmaceuticals Sustainability & Ethics
Teva publishes annual environmental, social, and governance (ESG) reports. The company has set targets for reducing greenhouse gas emissions across its manufacturing operations and has committed to aligning with the Science Based Targets initiative. Teva's manufacturing operations across Europe and North America are subject to extensive environmental regulation.
No Leaping Bunny, PETA, Vegan Society, or B Corp certification applies to Teva in the context of a pharmaceutical manufacturer.
Awards & Recognition
Teva has received recognition from pharmaceutical industry organizations for quality manufacturing practices, particularly its generic drug manufacturing, which is subject to regular FDA inspection and audit. The company's manufacturing sites have received FDA approval for compliance with current Good Manufacturing Practice (cGMP) standards.
Teva has been recognized by various ESG rating agencies for its sustainability reporting, though it has also faced significant criticism related to its opioid litigation and settlement history.
Teva Pharmaceuticals Recalls & Controversies
Teva has been involved in extensive litigation and controversy, most significantly related to the US opioid crisis and historical antitrust violations in the generic drug industry.
Opioid Settlement: Teva was one of the major pharmaceutical companies sued by US state and local governments for its role in distributing opioid medications. In 2022, Teva agreed to a settlement of approximately 4.25 billion US dollars over 13 years to resolve opioid-related claims from multiple US states and municipalities. The settlement included both cash payments and a provision of Narcan (naloxone) nasal spray. Teva had previously disputed its degree of responsibility but agreed to the settlement to avoid continued litigation.
Generic Drug Price-Fixing: In 2020 and subsequent years, Teva faced antitrust lawsuits from state attorneys general alleging that it had participated in a price-fixing conspiracy with other generic drug manufacturers. Teva has disputed the allegations but the litigation was ongoing as of June 2026, with several other generic manufacturers having reached prior settlements.
Bribery Allegations: In 2016, Teva agreed to pay approximately 519 million US dollars to resolve Foreign Corrupt Practices Act violations. The US Department of Justice and Securities and Exchange Commission alleged that Teva had paid bribes to government officials in Russia, Ukraine, and Mexico to win government pharmaceutical contracts. This was one of the largest FCPA settlements involving a pharmaceutical company at that time.
Manufacturing Quality Issues: Like all major pharmaceutical manufacturers, Teva has faced FDA warning letters and import alerts at various manufacturing facilities over the years for deviations from cGMP standards. Most have been resolved through remediation.
Copaxone Patent Litigation: Teva engaged in extensive litigation to protect Copaxone's patent exclusivity and delay generic competition. Courts ultimately allowed generic entry, and Teva's copaxone revenue declined substantially as a result.
Teva Pharmaceuticals Ownership: Pros & Cons
Advantages
- +World's largest generic drug manufacturer by volume, providing scale advantages in procurement and manufacturing
- +Diversified geographic revenue reduces dependence on any single market
- +Generic drug demand is largely non-cyclical; it is driven by aging populations and healthcare cost pressure rather than economic cycles
- +Austedo growth provides a branded revenue offset to generic pricing pressure
- +Restructuring completed under Schultz and Francis has substantially reduced the debt burden from the 2016 Allergan acquisition
- +First-to-file ANDA strategy can generate significant temporary exclusivity periods on new generic launches
Considerations
- -Opioid settlement commitments represent a cash outflow through approximately 2035
- -Antitrust litigation related to generic drug price-fixing is unresolved and represents financial and reputational risk
- -The US generic drug market continues to face structural pricing pressure from buyer consolidation
- -Copaxone revenue has declined dramatically from its peak, and no single product has yet replaced its profit contribution
- -The company's debt, while reduced, remains elevated and limits financial flexibility
- -Biosimilar competition in specialty products is intensifying, affecting the margins on branded products
Frequently Asked Questions About Teva Pharmaceuticals
Sources & Further Reading
Where to Buy
Disclosure: We may earn commission from purchases
Teva Pharmaceuticals on AmazonCompetitors to Teva Pharmaceuticals
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Sandoz Group | Switzerland | 1886 | Mass market | Global | All-ages |
Competitive Analysis
Market Positioning: Teva Pharmaceuticals competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Teva Pharmaceutical Industries Stock Information
Jobs at Teva Pharmaceutical Industries
Latest News About Teva Pharmaceuticals
Related Articles About Teva Pharmaceuticals
View more articles
Lexapro vs Zoloft: Who Makes Them and Does It Matter?
Two of the most prescribed antidepressants in America come from very different corporate backgrounds. Here is the ownership story behind Lexapro and Zoloft, and what it means for patients.
Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared
Pfizer and Johnson & Johnson are two of the most recognizable names in healthcare. But their brand portfolios look nothing alike. Here is a complete breakdown of what each company owns, how they got there, and what sets them apart.
15 Pharmacy Brands and Their Corporate Parents
CVS spent $69 billion to buy Aetna. Walgreens acquired Boots for $15 billion. Amazon paid $1 billion for PillPack. Here are 15 pharmacy brands, who owns them, and how a once-diverse industry collapsed into two dominant players.
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.
Acuvue
Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.